Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody

被引：0

作者：

Nelson, Michelle H. ^{[1
]}

Miller, Robert ^{[1
]}

Bader, Robert ^{[1
]}

Werchau, Doreen ^{[2
]}

Nilsson, Anneli ^{[2
]}

Ljung, Lill ^{[2
]}

Deronic, Adnan ^{[2
]}

Chunyk, Allison ^{[1
]}

Schultz, Lena ^{[2
]}

McMahan, Catherine ^{[1
]}

Bienvenue, David ^{[1
]}

Dahlman, Anna ^{[2
]}

Fritzell, Sara ^{[2
]}

Askmyr, Maria ^{[1
]}

Hernandez-Hoyos, Gabriela ^{[1
]}

机构：

[1] Aptevo Therapeut Inc, Seattle, WA USA

[2] Alligator Biosci AB, Lund, Sweden

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P642

引用

页数：2

共 50 条

[31] Activation of anti-tumor NK cells by gamma delta T lymphocytes through 4-1BB engagement
Chapoval, Andrei
Maniar, Amudhan
Zhang, Xiaoyu
Gastman, Brian R.
Pauza, C. David
Strome, Scott E.
JOURNAL OF IMMUNOLOGY, 2009, 182
[32] Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Curran, Michael A.
Kim, Myoungjoo
Montalvo, Welby
Al-Shamkhani, Aymen
Allison, James P.
PLOS ONE, 2011, 6 (04):
[33] HBM7008, A FIRST-IN-CLASS BISPECIFIC ANTIBODY TARGETING BOTH B7-H4 AND 4-1BB, EXHIBITS ROBUST ANTI-TUMOR IMMUNITY AND LOW TOXICITY THROUGH B7-H4-DIRECTED 4-1BB ACTIVATION
Huang, Bing
Du, Fangfang
Lv, Xiaocheng
Zhao, Jianxun
Chen, Fei
Lu, Zailian
Zhang, Yang
Chen, Victor
Gan, Xin
Zhao, Jiuqiao
He, Yun
Wu, Xiaodong
Rong, Yiping
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1099 - A1099
[34] Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation
Kim, JA
Averbook, BJ
Chambers, K
Rothchild, K
Kjaergaard, J
Papay, R
Shu, SY
CANCER RESEARCH, 2001, 61 (05) : 2031 - 2037
[35] The bispecific antibody KA-3002, targeting PSMA and 4-1BB, specifically enhances T cell activity within prostate tumors
Wu, Guojin
Liang, Jiabei
Peng, Hao
Hao, Feng
Liu, Tongtong
Ning, Jinying
CANCER RESEARCH, 2024, 84 (06)
[36] Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher
Cris Kamperschroer
Theodore Oliphant
Victoria A. Love
Paul D. Lira
Regis Doyonnas
Simon Bergqvist
Sangita M. Baxi
Allison Rohner
Amy C. Shen
Chunli Huang
Sharon A. Sokolowski
Leslie L. Sharp
Cancer Immunology, Immunotherapy, 2012, 61 : 1721 - 1733
[37] Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Fisher, Timothy S.
Kamperschroer, Cris
Oliphant, Theodore
Love, Victoria A.
Lira, Paul D.
Doyonnas, Regis
Bergqvist, Simon
Baxi, Sangita M.
Rohner, Allison
Shen, Amy C.
Huang, Chunli
Sokolowski, Sharon A.
Sharp, Leslie L.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (10) : 1721 - 1733
[38] Preclinical pharmacology of MP0310: A 4-1BB/FAP bispecific DARPin drug candidate promoting tumor-restricted T-cell costimulation
Link, Alexander
Hepp, Julia
Reichen, Christian
Schildknecht, Patricia
Tosevski, Ivana
Taylor, Joanna
Juglair, Laurent
Titz, Alexander
Matzner, Mirela
Bessey, Ralph
Zitt, Christof
Lemaillet, Guy
Herbst, Joerg
Dawson, Keith M.
Ji, Hong
Levitsky, Victor
Snell, Dan
Stumpp, Michael T.
Harstrick, Andreas
vom Baur, Elmar
CANCER RESEARCH, 2018, 78 (13)
[39] BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity
Han, Zhenyan
Shang, Chengzhang
Zhang, Yifu
An, Gao
Guo, Chaoshe
An, W. Frank
Yang, Yi
CANCER RESEARCH, 2024, 84 (06)
[40] Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1 / 4-1BB bispecific compound for tumor localized activation of the immune system.
Morales-Kastresana, Aizea
Pavlidou, Marina
Peper, Janet
Pattarini, Lucia
Barthels, Christian
Hansbauer, Eva-Maria
Aiba, Rachida Bel
Bossenmaier, Birgit
Scholer-Dahirel, Alix
Jaquin, Thomas
Gallou, Catherine
Blanc, Veronique
Rothe, Christine
Olwill, Shane
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →